Polycystic Kidney, Autosomal Dominant clinical trials
The registry lists 185 studies for Polycystic Kidney, Autosomal Dominant across more than 10 countries. 42 are recruiting or about to start. 172 of them are mainly about Polycystic Kidney, Autosomal Dominant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Polycystic Kidney, Autosomal Dominant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Mayo Clinic (15) · University of Colorado, Denver (12) · Otsuka Pharmaceutical Development & Commercialization, Inc. (10) · Mario Negri Institute for Pharmacological Research (10) · Jemincare (7) · Vertex Pharmaceuticals Incorporated (7) · Kyorin University (4) · Palladio Biosciences (4)
What is being tested here
Drugs under test in Polycystic Kidney, Autosomal Dominant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here SGLT2 inhibitors 1 open · Statins 1 open · mTOR inhibitors 10 · Tyrosine kinase inhibitors (TKIs) 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Nov 2026Drug-Drug Interactions of JMKX003142 in Healthy Participants · Jemincare
- Dec 2026A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD · Mayo Clinic
- Dec 2026Intrarenal Microvasculature in ADPKD · Mayo Clinic
- Dec 2026Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease · Loma Linda University
- Dec 2026Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Mayo Clinic
- Dec 2026NOX4 and Related Biomarkers in ADPKD · Mayo Clinic
- Dec 2026Somatosensory Phenotyping of ADPKD · Universitaire Ziekenhuizen KU Leuven
- Dec 2026Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose · Vertex Pharmaceuticals Incorporated
- Dec 2026Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease · Vertex Pharmaceuticals Incorporated
- Feb 2027Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease · Richard Fatica
Who these studies take
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger. 7 (23%) take children under 18. 2 (7%) are for women only and 1 (3%) for men only; 9 (30%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (13%) | 4 (13%) |
| 18 | 28 (93%) | 26 (87%) |
| 30 | 27 (90%) | 26 (87%) |
| 40 | 25 (83%) | 24 (80%) |
| 50 | 23 (77%) | 23 (77%) |
| 65 | 18 (60%) | 18 (60%) |
| 75 | 12 (40%) | 12 (40%) |
| 85 | 9 (30%) | 9 (30%) |
Across all 185 studies, recruiting or not: 61% stop at 75 or younger and 51% at 65; 16% take children; 2% are for women only and 1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Polycystic Kidney, Autosomal Dominant studies take
Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 39 mo18–53 · 17 studies | — | — |
| Interventional, no phase | 30 mo19–54 · 23 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseOct 30, 2026NCT07868926
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 185. Browse all 185 → or search them.
- Dietary Modulation of Urinary MCP-1 in ADPKDEnrolling by invitationNCT07651397Not applicable1 country
- Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT072600711 country
- A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic ImpairmentNot yet recruitingNCT07909070Phase 1
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseRecruitingNCT07868926Phase 11 country
- GBP-213 in Patients With Autosomal Dominant Polycystic Kidney DiseaseNot yet recruitingNCT07891364Early Phase 11 country
- Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT07228364Phase 13 countries
- ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT06902558Phase 212 countries
- Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesRecruitingNCT07792408Phase 11 country
- Bempedoic Acid Therapy for Polycystic Kidney DiseaseRecruitingNCT07282821Phase 21 country
- A Phase 1 Study of Single and Multiple Ascending Doses of GV-100RecruitingNCT07788014Phase 11 country
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifeRecruitingNCT05373264Phase 37 countries
- Managing Depressive Symptoms in ADPKDRecruitingNCT07745920Not applicable1 country
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseRecruitingNCT07280585Phase 34 countries
- Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003RecruitingNCT06714006Phase 13 countries
- Autosomal Dominant Polycystic Kidney Disease (ADPKD) StudyRecruitingNCT043380481 country
- Drug-Drug Interactions of JMKX003142 in Healthy ParticipantsNot yet recruitingNCT07565441Phase 1
- The German ADPKD Tolvaptan Treatment RegistryRecruitingNCT024975211 country
- Early PKD Observational Cohort StudyRecruitingNCT029367911 country
- RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDYRecruitingNCT075353851 country
- Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)RecruitingNCT04939935Phase 33 countries
- Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare DiseasesRecruitingNCT05996731Not applicable1 country
- A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy AdultsNot yet recruitingNCT07470177Phase 1
- Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy VolunteersNot yet recruitingNCT07463053Phase 1
- Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRecruitingNCT07454174Not applicable1 country
- Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney DiseaseNot yet recruitingNCT06786260Not applicable1 country
- A Prospective Observational Study of Foam Sclerotherapy .RecruitingNCT041116921 country
- Autosomal Dominant Polycystic Kidney Disease Somatic Mutation BiorepositoryEnrolling by invitationNCT039015211 country
- Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT043447691 country
- NOX4 and Related Biomarkers in ADPKDRecruitingNCT046306131 country
- Somatosensory Phenotyping of ADPKDRecruitingNCT069700281 country
- Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy SubjectsNot yet recruitingNCT07181265Phase 1
- Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT06800651Phase 21 country
- Glucagon-Like Peptide-1 Receptor Agonist in ADPKDRecruitingNCT06582875Phase 21 country
- Kidney Sodium Functional ImagingRecruitingNCT050141781 country
- Analysis of Patients With Autosomal Dominant Polycystic KidneyRecruitingNCT067591421 country
- Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease TreatmentRecruitingNCT06618638Not applicable1 country
- Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy SubjectsNot yet recruitingNCT06658964Phase 1
- Genetics in the Progression of NephropathiesRecruitingNCT064167611 country
- Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?Not yet recruitingNCT06100133Phase 2
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT05870007Phase 21 country
- A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver DiseaseRecruitingNCT05478083Phase 21 country
- Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT067475729 countries
- Role of ROS and cAMP-PKA Biomarkers in ADPKDActive, not recruitingNCT072171581 country
- Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06435858Phase 21 country
- Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Active, not recruitingNCT07161037Phase 28 countries
- A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06734234Phase 18 countries
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDActive, not recruitingNCT05281328Phase 2/34 countries
- Renal Denervation in ADPKD- RDN-ADPKD StudyActive, not recruitingNCT05460169Not applicable1 country
- Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKDActive, not recruitingNCT06496542Not applicable1 country